"2026 will be a year when ABL Bio's technology licensing and clinical trial results are both crucial." On the 14th (local time) in San Francisco, at the JP Morgan Healthcare Conference, Chief ...

SAN FRANCISCO — ABL Bio is closing in on another partnership with a global pharmaceutical company for its proprietary Grabody-B technology, a blood-brain barrier shuttle platform designed to improve ...

Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform. Under the terms announced Nov. 12, ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic. ABL, a Korean biotech that is partnered with companies ...

Progress Software Corporation (NASDAQ:PRGS) is one of the most undervalued technology stocks to buy according to analysts. On September 29, Progress Software announced the early customer review and ...

“Generic AI tools struggle with ABL due to limited training data and lack of domain context,” said John Ainsworth, EVP and General Manager, Application and Data Platform, Progress Software. “The ...

Progress Software (PRGS) announced early customer review and testing of the Progress OpenEdge MCP Connector for ABL, a purpose-built integration designed to accelerate development and modernization ...

Projects using OpenEdge ABL are having their source files skipped by codebase indexing. Adding these extensions to the fallback indexer will include them in search and context, so users can find ...